Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial
Min Yan(Zhengzhou University), Huajun Li(Jiangsu Hengrui Medicine (China)), Huiai Zeng(Zhengzhou University), Chongjian Zhang(Zhengzhou University), Limin Niu(Zhengzhou University), Huihui Sun(Zhengzhou University), Zhenzhen Liu(Zhengzhou University), Jing Wang(Zhengzhou University), Shengnan Zhao(Zhengzhou University), Mengwei Zhang(Jiangnan University), Yajing Feng(Zhengzhou University), Xiuchun Chen(Henan Cancer Hospital), Zhenduo Lu(Zhengzhou University), Huimin Lv(Zhengzhou University)
Cited by 14
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Chronic obstructive pulmonary disease in China: a nationwide prevalence study
|The Lancet Respiratory Medicine|2018|477
Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers
|Proceedings of the National Academy of Sciences|2014|167
Influenza vaccination rate and its association with chronic diseases in China: Results of a national cross-sectional study
|Vaccine|2020|96
IKKα restoration via EZH2 suppression induces nasopharyngeal carcinoma differentiation
|Nature Communications|2014|74